Virpax Pharmaceuticals Inc (VRPX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Virpax Pharmaceuticals Inc (VRPX) has a cash flow conversion efficiency ratio of 3.142x as of December 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.87 Million) by net assets ($-913.76K). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Virpax Pharmaceuticals Inc liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Virpax Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Virpax Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Virpax Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Virpax Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
PCI Biotech Holding ASA
OL:PCIB
|
-0.501x |
|
ImmuPharma PLC
LSE:IMM
|
-2.979x |
|
Kendrick Resources PLC
LSE:KEN
|
-0.071x |
|
Global Gas Corporation
NASDAQ:HGAS
|
0.137x |
|
Baltic Bridge S.A.
WAR:WIS
|
N/A |
|
Jpmorgan Global Core Real Assets Ltd
LSE:JARA
|
0.046x |
|
Water Ways Technologies Inc
V:WWT
|
0.002x |
|
Cirata plc
LSE:CRTA
|
-0.638x |
Annual Cash Flow Conversion Efficiency for Virpax Pharmaceuticals Inc (2018–2024)
The table below shows the annual cash flow conversion efficiency of Virpax Pharmaceuticals Inc from 2018 to 2024. For the full company profile with market capitalisation and key ratios, see Virpax Pharmaceuticals Inc (VRPX) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-913.76 Million | $-16.71 Billion | 18.290x | +459.04% |
| 2023-12-31 | $1.93 Million | $-9.85 Million | -5.094x | -373.23% |
| 2022-12-31 | $16.58 Million | $-17.85 Million | -1.076x | -177.47% |
| 2021-12-31 | $37.48 Million | $-14.54 Million | -0.388x | -218.11% |
| 2020-12-31 | $-4.22 Million | $-1.38 Million | 0.328x | -20.71% |
| 2019-12-31 | $-2.73 Million | $-1.13 Million | 0.414x | -72.55% |
| 2018-12-31 | $-1.19 Million | $-1.80 Million | 1.509x | -- |
About Virpax Pharmaceuticals Inc
Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an … Read more